Lasa Supergenerics Limited

(lohiyaakshay08) #188

Mgmt Interview

(lohiyaakshay08) #189

Board meeting for discussing on matters like Fund raising & reclassification of promoter’s list is Scheduled to be on 6th Jan.

(DK) #190

Is it normal to acquire shares at such lower prices than the current market price?

(sta) #191

THE price has increased only in last week . THIS is more of a transfer that was talked about in conference call. Both were promoters earlier.

(lohiyaakshay08) #192

My view: We generally see the price in the case of Preferential allotment & warrant. Since this transaction is between the father & son, it should not affect other shareholders.

(Nolan) #193

The deal and the agreed price is approved as per the SEBI’s Substantial Acquisition of Shares and Takeovers Regulations…so there is no question of any wrongdoing. Also, since the deal happened between two promoters off the market, there would be no material impact on market price besides a few random speculations about the fair price of the stock.

(Pradeep) #194

New CEP application filed for VET API range of product with EDQM – Europe

Mumbai, January 2, 2018: Lasa Supergenerics Limited, pioneer and amongst the leading player in manufacturing of Veterinary APIs in India through its catalyst chemistry expertise and fully backward integrated unit, announced that the Company has filed new CEP application for VET API product with EDQM (European Directorate for the Quality of Medicines) - Europe.

(Pradeep) #195

(Pradeep) #196

What I am unable to understand is that they already have a CEP for Fenbendazole that was issued in oct 14. What is this new CEP for? Is it for some new range of products?

(rahulparekh22) #197

Does anyone know how T2T group works and when exactly do the reviews happen and therefore when should we look out for a change if it happens?

(lohiyaakshay08) #198

Review happen on Quarterly basis. In my view it is due on 1st Feb

(dr ravindra gupta) #199

The role of a Certificate of Suitability (CEP) is to certify the compliance of a material with the requirements laid down in the relevant monograph of the European Pharmacopoeia. Active pharmaceutical ingredients for which a Certificate of Suitability has been granted are suitable for use in medicinal products.

(Pradeep) #200

So the CEP filed now is for a new product? If yes any idea on what that product is?

(Vivek) #201

any idea who has sold the 4.33 lak shares?

(Akhil) #202

Refer to the link:

They seem to be OSCL promoters.

(nkgambhir) #203

The 4.33 lakh shares have been sold by the " person acting in concert" (PAC) with Svaks Biotech. This PAC was holding 81.70 lakh shares of LASA . Now i do not know of any single promoter holding such a big chunk of LASA shares. I think this has got something to do with the mutual swapping of LASA and Omkar shares between the promoters of the two companies. More clarity wil emerge after tomorrows meeting .

(nkgambhir) #204

As per this link Mr. Omkar Herlekar has acquired 8 lakh shares of LASA and the mode of acquisition is mentioned as null, indicating an offmarket transaction. However this increases the personal holding of Mr Omkar herlekar by 3.5 % . Lot of action going on behind the scenes and the details will emerge after tomorrpws meeting.


Fund raising plans. No further details of use of proposed funds.

(jaindevyash) #206

In con call Mr Omkar says his Dad has 30 Lakh shares in Lasa but shareholding pattern uploaded on website shows only 13 Lakh shares

(jaindevyash) #207

So does that mean Mr Pravin herlekar have only 5 lakh shares of Lasa with him…because as on Sep 30 2017, he had some 13 lakh sahres of Lasa .